EMA approves Imvanex vaccine against monkeypox in EU
3 August 2022. Related: mpox (monkeypox), Coinfections and complications.
Simon Collins, HIV i-Base
On 22 July 2022, the EU committee responsible for reviewing medicines (CHMP) recommended extending the indication for Imvanex to include monkeypox (MPX). 
Imvanex was approved in the EU as a smallpox vaccine in 2013. 
Imvanex was approved in the US both for smallpox and monkeypox in 2019 where it is marketed as JYYNEOS. 
This included additional information from some studies. 
- EMA News. EMA recommends approval of Imvanex for the prevention of monkeypox disease. (22 July 2022).
- EMA. Imvanex product information. (2013).
- US FDA, FDA approves first live, non-replicating vaccine to prevent smallpox and monkeypox. (24 September 2019)
- US Office of Vaccines Research and Review (OVRR). Review memorandum for Jynneos vaccine. (2018)
This report was first published on 27 July 2022.